Characterization of T-cell responses to conserved regions of the HIV-1 proteome in BALB/c mice

Clinical and Vaccine Immunology

Volumn 21, Issue 11, 2014, Pages 1565-1572

  Ondondo, Beatrice ^a   Abdul Jawad, Sultan ^a   Bridgeman, Anne ^a   Hanke, Tomáš ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; PROTEOME; DRUG CARRIER; EPITOPE; RECOMBINANT PROTEIN; VIRAL PROTEIN;

ACTIVE IMMUNIZATION; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; EFFECTOR CELL; FEMALE; IMMUNE RESPONSE; IMMUNOGENICITY; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PEPTIDE MAPPING; T LYMPHOCYTE; ADENOVIRIDAE; ANIMAL; BAGG ALBINO MOUSE; CONSERVED SEQUENCE; GENE VECTOR; GENETICS; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOLOGY; ISOLATION AND PURIFICATION; SECRETION (PROCESS); VACCINIA VIRUS;

ADENOVIRIDAE; AIDS VACCINES; ANIMALS; CONSERVED SEQUENCE; DRUG CARRIERS; EPITOPES, T-LYMPHOCYTE; FEMALE; GENETIC VECTORS; HIV-1; INTERFERON-GAMMA; MICE, INBRED BALB C; RECOMBINANT PROTEINS; T-LYMPHOCYTES; VACCINIA VIRUS; VIRAL PROTEINS;

EID: 84914692091     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00587-14     Document Type: Article

References (43)

1. McMichael AJ, Haynes BF. 2012. Lessons learned from HIV-1 vaccine trials: new priorities and directions. Nat. Immunol. 13:423-427. http://dx.doi.org/10.1038/ni.2264.
2. Walker B, McMichael A. 2012. The T-cell response to HIV. Cold Spring Harb. Perspect. Med. 2:a007054. http://dx.doi.org/10.1101/cshperspect.a007054.
3. Bansal A, Gough E, Sabbaj S, Ritter D, Yusim K, Sfakianos G, Aldrovandi G, Kaslow RA, Wilson CM, Mulligan MJ, Kilby JM, Goepfert PA. 2005. CD8 T-cell responses in early HIV-1 infection are skewed towards high entropy peptides. AIDS 19:241-250.
4. Altfeld M, Kalife ET, Qi Y, Streeck H, Lichterfeld M, Johnston MN, Burgett N, Swartz ME, Yang A, Alter G, Yu XG, Meier A, Rockstroh JK, Allen TM, Jessen H, Rosenberg ES, Carrington M, Walker BD. 2006. HLA alleles associated with delayed progression to AIDS contribute strongly to the initial CD8(+) T cell response against HIV-1. PLoS Med. 3:e403. http://dx.doi.org/10.1371/journal.pmed.0030403.
5. Goonetilleke N, Liu MK, Salazar-Gonzalez JF, Ferrari G, Giorgi E, Ganusov VV, Keele BF, Learn GH, Turnbull EL, Salazar MG, Weinhold KJ, Moore S, Letvin N, Haynes BF, Cohen MS, Hraber P, Bhattacharya T, Borrow P, Perelson AS, Hahn BH, Shaw GM, Korber BT, McMichael AJ. 2009. The first T cell response to transmitted/founder virus contributes to the control of acute viremia in HIV-1 infection. J. Exp. Med. 206: 1253-1272. http://dx.doi.org/10.1084/jem.20090365.
6. Streeck H, Jolin JS, Qi Y, Yassine-Diab B, Johnson RC, Kwon DS, Addo MM, Brumme C, Routy JP, Little S, Jessen HK, Kelleher AD, Hecht FM, Sekaly RP, Rosenberg ES, Walker BD, Carrington M, Altfeld M. 2009. Human immunodeficiency virus type 1-specific CD8+ T-cell responses during primary infection are major determinants of the viral set point and loss of CD4+ T cells. J. Virol. 83:7641-7648. http://dx.doi.org/10.1128/JVI.00182-09.
7. Addo MM, Yu XG, Rathod A, Cohen D, Eldridge RL, Strick D, Johnston MN, Corcoran C, Wurcel AG, Fitzpatrick CA, Feeney ME, Rodriguez WR, Basgoz N, Draenert R, Stone DR, Brander C, Goulder PJ, Rosenberg ES, Altfeld M, WB D. 2003. Comprehensive epitope analysis of human immunodeficiency virus type 1 (HIV-1)-specific T-cell responses directed against the entire expressed HIV-1 genome demonstrate broadly directed responses, but no correlation to viral load. J. Virol. 77:2081-2092. http://dx.doi.org/10.1128/JVI.77.3.2081-2092.2003.
8. Hanke T. 2014. Conserved immunogens in prime-boost strategies for the next-generation HIV-1 vaccines. Expert Opin. Biol. Ther. 14:601-616. http://dx.doi.org/10.1517/14712598.2014.885946.
9. Letourneau S, Im E-J, Mashishi T, Brereton C, Bridgeman A, Yang H, Dorrell L, Dong T, Korber B, McMichael AJ, Hanke T. 2007. Design and pre-clinical evaluation of a universal HIV-1 vaccine. PLoS One 2:e984. http://dx.doi.org/10.1371/journal.pone.0000984.
10. Im E-J, Hong JP, Roshorm Y, Bridgeman A, Létourneau S, Liljeström P, Potash MJ, Volsky DJ, McMichael AJ, Hanke T. 2011. Protective efficacy of serially up-ranked subdominant CD8+ T cell epitopes against virus challenges. PLoS Pathog. 7:e1002041. http://dx.doi.org/10.1371/journal.ppat.1002041.
11. Knudsen ML, Mbewe-Mvula A, Rosario M, Johansson DX, Kakoulidou M, Bridgeman A, Reyes-Sandoval A, Nicosia A, Ljungberg K, Hanke T, Liljestrom P. 2012. Superior induction of T cell responses to conserved HIV-1 regions by electroporated alphavirus replicon DNA compared to conventional plasmid DNA vaccine. J. Virol. 86:4082-4090. http://dx.doi.org/10.1128/JVI.06535-11.
12. Koopman G, Beenhakker N, Nieuwenhuis I, Doxiadis G, Mooij P, Drijfhout JW, Koestler J, Hanke T, Fagrouch Z, Verschoor EJ, Bontrop RE, Wagner R, Bogers WM, Melief CJ. 2013. DNA/long peptide vaccination against conserved regions of SIV induces partial protection against SIVmac251 challenge. AIDS 27:2841-2851. http://dx.doi.org/10.1097/QAD.0000000000000047.
13. Ondondo BO, Yang H, Dong T, di Gleria K, Suttill A, Conlon C, Brown D, Williams P, Rowland-Jones SL, Hanke T, McMichael AJ, Dorrell L. 2006. Immunisation with recombinant modified vaccinia virus Ankara expressing HIV-1 gag in HIV-1-infected subjects stimulates broad functional CD4+ T cell responses. Eur. J. Immunol. 36:2585-2594. http://dx.doi.org/10.1002/eji.200636508.
14. Rosario M, Borthwick N, Stewart-Jones GB, Mbewe-Mwula A, Bridgeman A, Colloca S, Montefiori D, McMichael AJ, Nicosia A, Drijfhout JW, Melief CJM, Hanke T. 2012. Prime-boost regimens with adjuvanted synthetic long peptides elicit T cells and antibodies to conserved regions of HIV-1 in macaques. AIDS 26:275-284. http://dx.doi.org/10.1097/QAD.0b013e32834ed9b2.
15. Rosario M, Bridgeman A, Quakkelaar ED, Quigley MF, Hill BJ, Knudsen ML, Ammendola V, Ljungberg K, Borthwick N, Im EJ, McMichael AJ, Drijfhout JW, Greenaway HY, Venturi V, Douek DC, Colloca S, Liljestrom P, Nicosia A, Price DA, Melief CJ, Hanke T. 2010. Long peptides induce polyfunctional T cells against conserved regions of HIV-1 with superior breadth to single-gene vaccines in macaques. Eur. J. Immunol. 40:1973-1984. http://dx.doi.org/10.1002/eji.201040344.
16. Borthwick N, Ahmed T, Ondondo B, Hayes P, Rose A, Ebrahimsa U, Hayton EJ, Black A, Bridgeman A, Rosario M, Hill AV, Berrie E, Moyle S, Frahm N, Cox J, Colloca S, Nicosia A, Gilmour J, McMichael AJ, Dorrell L, Hanke T. 2014. Vaccine-elicited human T cells recognizing conserved protein regions inhibit HIV-1. Mol. Ther. 22:464-475. http://dx.doi.org/10.1038/mt.2013.248.
17. Nakagawa Y, Kikuchi H, Takahashi H. 2007. Molecular analysis of TCR and peptide/MHC interaction using P18-I10-derived peptides with a single D-amino acid substitution. Biophys. J. 92:2570-2582. http://dx.doi.org/10.1529/biophysj.106.095208.
18. Takahashi H, Cohen J, Hosmalin A, Cease KB, Houghten R, Cornette JL, DeLisi C, Moss B, Germain RN, Berzofsky JA. 1988. An immunodominant epitope of the human immunodeficiency virus envelope glycoprotein gp160 recognized by class I major histocompatibility moleculerestricted murine cytotoxic T lymphocytes. Proc. Natl. Acad. Sci. U. S. A. 85:3105-3109. http://dx.doi.org/10.1073/pnas.85.9.3105.
19. Hanke T, Schneider J, Gilbert SC, Hill AVS, McMichael A. 1998. DNA multi-CTL epitope vaccines for HIV and Plasmodium falciparum: immunogenicity in mice. Vaccine 16:426-435. http://dx.doi.org/10.1016/S0264-410X(97)00296-X.
20. Hanke T, McMichael AJ. 2000. Design and construction of an experimental HIV-1 vaccine for a year-2000 clinical trial in Kenya. Nat. Med. 6:951-955. http://dx.doi.org/10.1038/79626.
21. Tatsis N, Fitzgerald JC, Reyes-Sandoval A, Harris-McCoy KC, Hensley SE, Zhou D, Lin SW, Bian A, Xiang ZQ, Iparraguirre A, Lopez-Camacho C, Wherry EJ, Ertl HC. 2007. Adenoviral vectors persist in vivo and maintain activated CD8+ T cells: implications for their use as vaccines. Blood 110:1916-1923. http://dx.doi.org/10.1182/blood-2007-02-062117.
22. Deng Y, Yewdell JW, Eisenlohr LC, Bennink JR. 1997. MHC affinity, peptide liberation, T cell repertoire, and immunodominance all contribute to the paucity of MHC class I-restricted peptides recognized by antiviral CTL. J. Immunol. 158:1507-1515.
23. Didierlaurent A, Ramirez JC, Gherardi M, Zimmerli SC, Graf M, Orbea HA, Pantaleo G, Wagner R, Esteban M, Kraehenbuhl JP, Sirard JC. 2004. Attenuated poxviruses expressing a synthetic HIV protein stimulate HLA-A2-restricted cytotoxic T-cell responses. Vaccine 22:3395-3403. http://dx.doi.org/10.1016/j.vaccine.2004.02.025.
24. Larke N, Im E-J, Wagner R, Williamson C, Williamson A-L, McMichael AJ, Hanke T. 2007. Combined single-clade candidate HIV-1 vaccines induce T cell responses limited by multiple forms of in vivo immune interference. Eur. J. Immunol. 37:566-577. http://dx.doi.org/10.1002/eji.200636711.
25. Casimiro DR, Tang A, Perry HC, Long RS, Chen M, Heidecker GJ, Davies ME, Freed DC, Persaud NV, Dubey S, Smith JG, Havlir D, Richman D, Chastain MA, Simon AJ, Fu TM, Emini EA, Shiver JW. 2002. Vaccine-induced immune responses in rodents and nonhuman primates by use of a humanized human immunodeficiency virus type 1 pol gene. J. Virol. 76:185-194. http://dx.doi.org/10.1128/JVI.76.1.185-194.2002.
26. Cellini S, Fortini C, Gallerani E, Destro F, Cofano EB, Caputo A, Gavioli R. 2008. Identification of new HIV-1 Gag-specific cytotoxic T lymphocyte responses in BALB/c mice. Virol. J. 5:81. http://dx.doi.org/10.1186/1743-422X-5-81.
27. Mata M, Travers PJ, Liu Q, Frankel FR, Paterson Y. 1998. The MHC class I-restricted immune response to HIV-gag in BALB/c mice selects a single epitope that does not have a predictable MHC-binding motif and binds to Kd through interactions between a glutamine at P3 and pocket D. J. Immunol. 161:2985-2993.
28. Achour A, Persson K, Harris RA, Sundback J, Sentman CL, Lindqvist Y, Schneider G, Karre K. 1998. The crystal structure of H-2Dd MHC class I complexed with the HIV-1-derived peptide P18-I10 at 2.4 A resolution: implications for T cell and NK cell recognition. Immunity 9:199-208. http://dx.doi.org/10.1016/S1074-7613(00)80602-0.
29. Li H, Natarajan K, Malchiodi EL, Margulies DH, Mariuzza RA. 1998. Three-dimensional structure of H-2Dd complexed with an immunodominant peptide from human immunodeficiency virus envelope glycoprotein 120. J. Mol. Biol. 283:179-191. http://dx.doi.org/10.1006/jmbi.1998.2091.
30. Shirai M, Pendleton CD, Berzofsky JA. 1992. Broad recognition of cytotoxic T cell epitopes from the HIV-1 envelope protein with multiple class I histocompatibility molecules. J. Immunol. 148:1657-1667.
31. Alexander-Miller MA, Parker KC, Tsukui T, Pendleton CD, Coligan JE, Berzofsky JA. 1996. Molecular analysis of presentation by HLA-A2.1 of a promiscuously binding V3 loop peptide from the HIV-envelope protein to human cytotoxic T lymphocytes. Int. Immunol. 8:641-649. http://dx.doi.org/10.1093/intimm/8.5.641.
32. Afolabi MO, Ndure J, Drammeh A, Darboe F, Mehedi S-R, Rowland-Jones SL, Borthwick N, Black A, Ambler G, John-Stewart GC, Reilly M, Hanke T, Flanagan KL. 2013. A phase I randomized clinical trial of candidate human immunodeficiency virus type 1 vaccine MVA.HIVA administered to Gambian infants. PLoS One 8:e78289. http://dx.doi.org/10.1371/journal.pone.0078289.
33. Dorrell L, Yang H, Iversen AK, Conlon C, Suttill A, Lancaster M, Dong T, Cebere I, Edwards A, Rowland-Jones S, Hanke T, McMichael AJ. 2005. Therapeutic immunization of highly active antiretroviral therapytreated HIV-1-infected patients: safety and immunogenicity of an HIV-1 gag/poly-epitope DNA vaccine. AIDS 19:1321-1323. http://dx.doi.org/10.1097/01.aids.0000180104.65640.16.
34. Dorrell L, Yang H, Ondondo B, Dong T, di Gleria K, Suttill A, Conlon C, Brown D, Williams P, Bowness P, Goonetilleke N, Rostron T, Rowland-Jones S, Hanke T, McMichael AJ. 2006. Expansion and diversification of HIV-1-specific T cells following immunisation of HIV-1-infected individuals with a recombinant modified vaccinia virus Ankara/HIV-1 gag vaccine. J. Virol. 80:4705-4716. http://dx.doi.org/10.1128/JVI.80.10.4705-4716.2006.
35. Goonetilleke N, Moore S, Dally L, Winstone N, Mahmoud N, Cebere I, Pinheiro S, Gillespie G, Brown D, Loach V, Roberts J, Guimaraes-Walker A, Hayes P, Loughran K, Smith C, Fast P, Dorrell L, Hanke T, McMichael A. 2006. Prime-boost vaccination with recombinant DNA and MVA expressing HIV-1 clade A gag and immunodominant CTL epitopes induces multi-functional HIV-1-specific T cells in healthy subjects. J. Virol. 80:4717-4728. http://dx.doi.org/10.1128/JVI.80.10.4717-4728.2006.
36. Jaoko W, Nakwagala FN, Anzala O, Manyonyi GO, Birungi J, Nanvubya A, Bashir F, Bhatt K, Ogutu H, Wakasiaka S, Matu L, Waruingi W, Odada J, Oyaro M, Indangasi J, Ndinya-Achola J, Konde C, Mugisha E, Fast P, Schmidt C, Gilmour J, Tarragona T, Smith C, Barin B, Dally L, Johnson B, Muluubya A, Nielsen L, Hayes P, Boaz M, Hughes P, Hanke T, McMichael A, Bwayo J, Kaleebu P. 2008. Safety and immunogenicity of recombinant low-dosage HIV-1 A vaccine candidates vectored by plasmid pTHr DNA or modified vaccinia virus Ankara (MVA) in humans in East Africa. Vaccine 26:2788-2795. http://dx.doi.org/10.1016/j.vaccine.2008.02.071.
37. Mwau M, Cebere I, Sutton J, Chikoti P, Winstone N, Wee EG, Beattie T, Chen Y-H, Dorrel L, McShane H, Schmidt C, Brooks M, Patel S, Roberts J, Conlon C, Rowland-Jones S, Bwayo J, McMichael AJ, Hanke T. 2004. An HIV-1 clade A vaccine in clinical trials: stimulation of HIVspecific T cell responses byDNAand recombinant modified vaccinia virus Ankara (MVA) vaccines in humans. J. Gen. Virol. 85:911-919. http://dx.doi.org/10.1099/vir.0.19701-0.
38. Njuguna IN, Ambler G, Reilly M, Ondondo B, Kanyugo M, Lohman-Payne B, Gichuhi C, Borthwick N, Black A, Mehedi S-R, Maleche-Obimbo E, Chohan B, John-Stewart GC, Jaoko W, Hanke T. 27 August 2014. PedVacc 002: a phase I randomized clinical trial of MVA.HIVA vaccine administered to infants born to human immunodeficiency virus type 1-infected mothers in Nairobi. Vaccine http://dx.doi.org/10.1016/j.vaccine.2014.08.034.
39. Peters BS, Jaoko W, Vardas E, Panayotakopoulos G, Fast P, Schmidt C, Gilmour J, Bogoshi M, Omosa-Manyonyi G, Dally L, Klavinskis L, Farah B, Tarragona T, Bart PA, Robinson A, Pieterse C, Stevens W, Thomas R, Barin B, McMichael AJ, McIntyre JA, Pantaleo G, Hanke T, Bwayo J. 2007. Studies of a prophylactic HIV-1 vaccine candidate based on modified vaccinia virus Ankara (MVA) with and without DNA priming: effects of dosage and route on safety and immunogenicity. Vaccine 25:2120-2127. http://dx.doi.org/10.1016/j.vaccine.2006.11.016.
40. Winstone N, Guimarães-Walker A, Roberts J, Brown D, Loach V, Goonetilleke N, Hanke T, McMichael AJ. 2009. Increased detection of proliferating, polyfunctional, HIV-1-specific T cells in DNA-MVA vaccinated human volunteers by cultured IFN-γ ELISPOT assay. Eur. J. Immunol. 39:975-985. http://dx.doi.org/10.1002/eji.200839167.
41. Yang H, Dong T, Turnbull E, Ranasinghe S, Ondondo B, Goonetilleke N, Winstone N, di Gleria K, Bowness P, Conlon C, Borrow P, Hanke T, McMichael A, Dorrell L. 2007. Broad TCR usage in functional HIV-1-specific CD8+ T cell expansions driven by vaccination during highly active antiretroviral therapy. J. Immunol. 179:597-606. http://dx.doi.org/10.4049/jimmunol.179.1.597.
42. Ewer KJ, O'Hara GA, Duncan CJ, Collins KA, Sheehy SH, Reyes-Sandoval A, Goodman AL, Edwards NJ, Elias SC, Halstead FD, Longley RJ, Rowland R, Poulton ID, Draper SJ, Blagborough AM, Berrie E, Moyle S, Williams N, Siani L, Folgori A, Colloca S, Sinden RE, Lawrie AM, Cortese R, Gilbert SC, Nicosia A, Hill AV. 2013. Protective CD8(+) T-cell immunity to human malaria induced by chimpanzee adenovirus-MVA immunisation. Nat. Commun. 4:2836. http://dx.doi.org/10.1038/ncomms3836.
43. Sheehy SH, Duncan CJ, Elias SC, Choudhary P, Biswas S, Halstead FD, Collins KA, Edwards NJ, Douglas AD, Anagnostou NA, Ewer KJ, Havelock T, Mahungu T, Bliss CM, Miura K, Poulton ID, Lillie PJ, Antrobus RD, Berrie E, Moyle S, Gantlett K, Colloca S, Cortese R, Long CA, Sinden RE, Gilbert SC, Lawrie AM, Doherty T, Faust SN, Nicosia A, Hill AV, Draper SJ. 2012. ChAd63-MVA-vectored blood-stage malaria vaccines targeting MSP1 and AMA1: assessment of efficacy against mosquito bite challenge in humans. Mol. Ther. 20:2355-2368. http://dx.doi.org/10.1038/mt.2012.223.